Browsing by Author "Sezgin G."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey - GALATA study
    (Informa Healthcare, 2015) Ayvaz G.; Keskin L.; Akin T.F.; Dokmetas H.S.; Tasan E.; Ar I.B.; Uren E.; Akber T.; Akdeniz Y.; Bambul N.; Bayraktaroglu T.; Borlu F.; Boz M.; Bozoglu E.; Buyukbese M.A.; Canberk A.; Comlekci A.; Delibasi T.; Demir S.; Eskioglu E.; Guler S.; Gulkan S.; Hekimsoy Z.; Karaca Z.; Keskin M.; Koca N.; Korkmaz H.; Onder E.; Ozisik L.; Peru C.; Sahin M.; Saygili F.; Serin S.; Sezer H.; Sezgin G.; Tasci I.; Tasliyurt T.; Torun A.N.; Tura Bahadir C.; Gursoy Yener G.; Yigit Z.
    Objective: To evaluate tolerability/safety and the efficacy of the combination of vildagliptin plus metformin in a real-life population of patients with type 2 diabetes mellitus (T2DM). Research design and methods: This multicenter, single-arm, 6 month, observational, prospective cohort study was conducted at 39 centers across Turkey. T2DM patients on vildagliptin and metformin for ≤4 weeks were enrolled regardless of their previous antidiabetic therapy. Main outcome measures: Efficacy was evaluated by measuring hemoglobin A1c (HbA1c) levels. Tolerability/safety parameters evaluated included hypoglycemic events, gastrointestinal events, peripheral edema and weight gain. Results: This study enrolled 665 patients with a mean±standard deviation (SD) age of 55.1±10.2 years and female predominance (n=394, 59.2%). Safety was assessed in all enrolled patients. Hypoglycemia was reported in 10 (1.5%) patients (95% confidence interval = 0.8-2.7%). Efficacy was assessed in 289 (43.5%) patients treated for 6±1 months; these patients showed a mean decrease in HbA1c of 0.8% from baseline value of 7.8% (p<0.001). The percentages of patients who achieved HbA1c targets of ≤6.5% and ≤7.0% were significantly increased, from 10.7% to 33.6% and from 22.1% to 52.6%, respectively (p<0.001 each). The decrease in HbA1c was independent of baseline HbA1c (≤8% vs. 8-10% vs. ≥10%), age (≤65 vs. >65 years) and body mass index (<30 vs. ≥30 kg/m2) (p<0.001 each). In total, 136 adverse events (AEs) were observed in 71 (10.7%) patients; 10 (1.5%) patients experienced hypoglycemia and gastrointestinal AEs were most commonly reported (n=29, 4.4%). Conclusions: In a 'real-life' setting, the vildagliptin and metformin combination was associated with significant improvements in reaching target HbA1c levels, even in elderly and obese patients with T2DM. Moreover, vildagliptin and metformin demonstrated a good overall tolerability/safety profile. © 2015 All rights reserved: reproduction in whole or part not permitted.
  • No Thumbnail Available
    Item
    Determining the Binding Capacities of Cr (VI) and Zn (II) Ions of Oscillatoria sp.
    (Sakarya University, 2020) Sezgin G.; Yildiz Ş.; Şentürk T.
    This study aimed to determine the removal capacity for Cr (VI) and Zn (II) ions from high concentration of aqueous solutions by using Oscillatoria microalgae. In the biosorption process, live and dead Oscillatoria cells were exposed for 24 hours to Cr and Zn metals of different concentrations (2.5, 5 and 10 mg/L). In addition, chlorophyll-a analysis have been made to examine the effects on cell metabolism of chromium and zinc metals. The best metal removal percentages was obtained; of chromium ion is 46.74% with dead cells and for zinc ion 82.53% with living cells. Chlorophyll-a analysis shows that when the metals separately applied on Oscillatoria cells, chlorophyll-a content of organism increase but when metals together applied decrease of chlorophyll-a content was observed. For this study, Freundlich model best fitted the data for two metal ions with 1/n value <1. This study revealed that Oscillatoria cells were an effective adsorbent for removal of the two heavy metals, especially Zn ions from aqueous solutions due to its high efficiency of Zn adsorption. It shows that it is a kind of potential for this heavy metal removal operations. © 2020, Sakarya University. All rights reserved.
  • No Thumbnail Available
    Item
    Outcomes of high-risk breast lesions diagnosed using image-guided core needle biopsy: results from a multicenter retrospective study
    (Galenos Publishing House, 2023) Oktay A.; Aslan Ö.; Taşkın F.; Tunçbilek N.; İçten S.G.E.; Balcı P.; Arıbal M.E.; Çelik L.; Örgüç İ.Ş.; Demirkazık F.B.; Gültekin S.; Aydın A.M.; Durmaz E.; Kul S.; Binokay F.; Çetin M.; Emlik G.D.; Akpınar M.G.; Voyvoda S.N.K.; Polat A.V.; Akın I.B.; Yıldız Ş.; Poyraz N.; Özsoy A.; Öztekin P.S.; Elverici E.; Bayrak İ.K.; İkizceli T.; Dinç F.; Sezgin G.; Gülşen G.; Tunçbilek I.; Yalçın S.R.; Çolakoğlu G.; Ağlamış S.; Yılmaz R.; Rona G.; Durhan G.; Güner D.C.; Yabul F.Ç.; Karabekmez L.G.; Tutar B.; Göktaş M.; Buğdaycı O.; Suner A.; Özdemir N.
    Purpose: The clinical management of high-risk lesions using image-guided biopsy is challenging. This study aimed to evaluate the rates at which such lesions were upgraded to malignancy and identify possible predictive factors for upgrading high-risk lesions. Methods: This retrospective multicenter analysis included 1.343 patients diagnosed with high-risk lesions using an image-guided core needle or vacuum-assisted biopsy (VAB). Only patients managed using an excisional biopsy or with at least one year of documented radiological follow-up were included. For each, the Breast Imaging Reporting and Data System (BI-RADS) category, number of samples, needle thickness, and lesion size were correlated with malignancy upgrade rates in different histologic subtypes. Pearson's chi-squared test, the Fisher-Freeman-Halton test, and Fisher's exact test were used for the statistical analyses. Results: The overall upgrade rate was 20.6%, with the highest rates in the subtypes of intraductal papilloma (IP) with atypia (44.7%; 55/123), followed by atypical ductal hyperplasia (ADH) (38.4%; 144/375), lobular neoplasia (LN) (12.7%; 7/55), papilloma without atypia (9.4%; 58/611), flat epithelial atypia (FEA) (8.7%; 10/114), and radial scars (RSs) (4.6%; 3/65). There was a significant relationship between the upgrade rate and BI-RADS category, number of samples, and lesion size Lesion size was the most predictive factor for an upgrade in all subtypes. Conclusion: ADH and atypical IP showed considerable upgrade rates to malignancy, requiring surgical excision. The LN, IP without atypia, pure FEA, and RS subtypes showed lower malignancy rates when the BI-RADS category was lower and in smaller lesions that had been adequately sampled using VAB. After being discussed in a multidisciplinary meeting, these cases could be managed with follow-up instead of excision. © 2023, Galenos Publishing House. All rights reserved.